on October 24, 2022
David Gornoski Interviews Dr. Paul Alexander
“If a society can’t fight for children, there is no point in having a society.” David Gornoski is joined by former HHS scientist Dr. Paul Alexander who talks about the next event where he is scheduled to speak, whether children need vaccines, how the Biden administration carries water for vaccine manufacturers, the Boston lab-made Covid strain, and more. Plus, David talks about his article on Blake Master’s pro-liberty and pro-family movement to DC.
on October 24, 2022
OPEN THE BOOKS GETS ITS HANDS ON DR.FAUCI’S CALENDAR
Dr. Anthony Fauci was forced to hand over his calendar to Open The Book’s Adam Andrzejewski. He shares what he’s uncovered with Emerald Robinson.
on October 24, 2022
Long COVID and the Medical System
Given the dysfunction in the American medical system in the response to Acute COVID, it is not surprising that this dysfunction extends to the treatment of Post-Acute Sequela of COVID-19 (PASC) or Long COVID. The problem with the system’s response to the long-term manifestations of the acute disease is the average medical provider in the
on October 24, 2022
Cloud Nine at the FLCCC Inaugural Conference
Science, and specifically the practice of medicine, requires discourse. Discourse includes many forms, from lively debates on opposing hypotheses to collaboration and sharing of ideas. This past weekend at the FLCCC Inaugural Educational Conference of Spike Induced Diseases (https://covid19criticalcare.com/flccc-educational-conference-october-15-2022/), collaboration, mutual respect, and knowledge sharing were the foundation of the event.
on October 24, 2022
The Writing is on the Wall, Even on Fox News
The writing is on the wall, even at Fox News. The obvious collusion between big Pharma and the American government is completely out of control. We have been waiting for a Rosa Parks moment, this might be it.
on October 24, 2022
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
The SARS-CoV-2 Omicron BA.2.75 variant emerged in May 2022. BA.2.75 is a BA.2 descendant but is phylogenetically distinct from BA.5, the currently predominant BA.2 descendant. Here, we show that BA.2.75 has a greater effective reproduction number and different immunogenicity profile than BA.5. We determined the sensitivity of BA.2.75 to vaccinee and convalescent sera as well as a panel of clinically available antiviral drugs and antibodies. Antiviral drugs largely retained potency, but antibody sensitivity varied depending on several key BA.2.75-specific substitutions. The BA.2.75 spike exhibited a profoundly higher affinity for its human receptor, ACE2. Additionally, the fusogenicity, growth efficiency in human alveolar epithelial cells, and intrinsic pathogenicity in hamsters of BA.2.75 were greater than those of BA.2. Our multilevel investigations suggest that BA.2.75 acquired virological properties independent of BA.5, and the potential risk of BA.2.75 to global health is greater than that of BA.5.